Skip to main content

CORRECTION article

Front. Pharmacol., 07 March 2022
Sec. Inflammation Pharmacology
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.867017

Corrigendum: Impact of Non-Persistence on Healthcare Resource Utilization Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study

www.frontiersin.orgNuria Carballo1,2* www.frontiersin.orgEnric Garcia-Alzórriz3 www.frontiersin.orgOlivia Ferrández1,2 www.frontiersin.orgMaría Eugenia Navarrete-Rouco1 www.frontiersin.orgXavier Durán-Jordà4 www.frontiersin.orgCarolina Pérez-García5 www.frontiersin.orgJordi Monfort2,5 www.frontiersin.orgFrancesc Cots3 www.frontiersin.orgSantiago Grau1,2
  • 1Pharmacy Department, Hospital del Mar – Parc de Salut Mar, Barcelona, Spain
  • 2Universitat Autònoma de Barcelona, Barcelona, Spain
  • 3Management Control Department, Hospital del Mar – Parc de Salut Mar, Barcelona, Spain
  • 4Methodology and Biostatistics Support Unit, Institute Hospital del Mar for Medical Research (IMIM), Barcelona, Spain
  • 5Department of Rheumatology, Hospital del Mar – Parc de Salut Mar, Barcelona, Spain

A Corrigendum on
Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study

by Carballo, N., Garcia-Alzórriz, E., Ferrández, O., Navarrete-Rouco, M. E., Durán-Jordà, X., Pérez-García, C., Monfort, J., Cots, F., and Grau, S. (2021). Front. Pharmacol. 12:752879. doi: 10.3389/fphar.2021.752879

In the published article, there was an error regarding the affiliations for Nuria Carballo, Olivia Ferrández, Jordi Monfort and Santiago Grau. These authors all have an additional affiliation, listed as “Universitat Autònoma de Barcelona, Barcelona, Spain”.

In addition, there was an error in the Acknowledgements section in the original article. The following statement was should have been included:

“This study is part of a PhD programme in Medicine of the Universitat Autònoma de Barcelona. This study was presented, in part, as a poster at the EULAR Virtual Congress, 2–5 June 2021 in Paris, France.”

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: rheumatic disease, biologics, persistence, healthcare resource utilization and costs, anti TNF agents

Citation: Carballo N, Garcia-Alzórriz E, Ferrández O, Navarrete-Rouco ME, Durán-Jordà X, Pérez-García C, Monfort J, Cots F and Grau S (2022) Corrigendum: Impact of Non-Persistence on Healthcare Resource Utilization Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study. Front. Pharmacol. 13:867017. doi: 10.3389/fphar.2022.867017

Received: 31 January 2022; Accepted: 31 January 2022;
Published: 07 March 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Carballo, Garcia-Alzórriz, Ferrández, Navarrete-Rouco, Durán-Jordà, Pérez-García, Monfort, Cots and Grau. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Nuria Carballo, ncarballo@psmar.cat

Download